Literature DB >> 32146594

Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.

Jing Ming1, Wei-Yi Liu1, Hai-Yan Xiao1, Yong-Gang Xu1, Rou Ma1, Xiao-Mei Hu2.   

Abstract

Qinghuang Powder (QHP), an oral arsenic, has become an effective drug in the treatment of myelodysplastic syndromes (MDS) in Xiyuan Hospital, China Academy of Chinese Medical Sciences for many years, and the action mechanism of the compound or active ingredient As2S2 of QHP has been elucidated. Considering the relatively safety, chemotherapy-free and convenient oral profile, QHP is widely used in the clinical treatment for MDS patients, especially for elderly patients. In this review, the authors document the efficacy and safety of oral arsenic-containing compound QHP in the treatment of MDS, with a special focus on the association of efficacy of QHP with the cytogenetics, prognostic risk, DNA methylation, gene mutation, blood arsenic concentration, mechanism of action of As2S2 and the countermeasures against adverse reactions of gastrointestinal tract.
© 2020. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Chinese medicine; Qinghuang Powder; arsenic; myelodysplastic syndromes; review

Mesh:

Substances:

Year:  2020        PMID: 32146594     DOI: 10.1007/s11655-020-3254-9

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   2.626


  33 in total

1.  Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China.

Authors:  Xiao-mei Hu; Feng Liu; Rou Ma
Journal:  Chin J Integr Med       Date:  2010-08-10       Impact factor: 1.978

2.  Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Authors:  Michael Lübbert; Stefan Suciu; Liliana Baila; Björn Hans Rüter; Uwe Platzbecker; Aristoteles Giagounidis; Dominik Selleslag; Boris Labar; Ulrich Germing; Helmut R Salih; Filip Beeldens; Petra Muus; Karl-Heinz Pflüger; Corneel Coens; Anne Hagemeijer; Hans Eckart Schaefer; Arnold Ganser; Carlo Aul; Theo de Witte; Pierre W Wijermans
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.

Authors:  Hanneke M van der Straaten; Anja van Biezen; Ronald Brand; Anton V M B Schattenberg; Roel M Egeler; Renée M Barge; Jan J Cornelissen; Harry C Schouten; Gert J Ossenkoppele; Leo F Verdonck
Journal:  Haematologica       Date:  2005-10       Impact factor: 9.941

5.  A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.

Authors:  Zheng-Ping Yu; Jia-Hua Ding; Ai-Ning Sun; Zheng Ge; Bao-An Chen; De-Pei Wu
Journal:  Stem Cells Dev       Date:  2017-06-12       Impact factor: 3.272

Review 6.  Genetic abnormalities and pathophysiology of MDS.

Authors:  Naoko Hosono
Journal:  Int J Clin Oncol       Date:  2019-05-15       Impact factor: 3.402

7.  Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.

Authors:  Esther Schuler; Natalie Zadrozny; Sabine Blum; Thomas Schroeder; Corinna Strupp; Barbara Hildebrandt; Andrea Kündgen; Norbert Gattermann; Carlo Aul; Mustafa Kondakci; Guido Kobbe; Rainer Haas; Ulrich Germing
Journal:  Ann Hematol       Date:  2018-08-04       Impact factor: 3.673

Review 8.  Myelodysplastic syndromes.

Authors:  Lionel Adès; Raphael Itzykson; Pierre Fenaux
Journal:  Lancet       Date:  2014-03-21       Impact factor: 79.321

9.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors:  Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal:  Blood       Date:  2007-09-24       Impact factor: 22.113

10.  Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Authors:  Dana E Rollison; Nadia Howlader; Martyn T Smith; Sara S Strom; William D Merritt; Lynn A Ries; Brenda K Edwards; Alan F List
Journal:  Blood       Date:  2008-04-28       Impact factor: 22.113

View more
  1 in total

1.  Effects of Qinghuang Powder on Acute Myeloid Leukemia Based on Network Pharmacology, Molecular Docking, and In Vitro Experiments.

Authors:  Ying-Jian Zeng; Min Wu; Huan Zhang; Xin-Ping Wu; Lu Zhou; Na Wan; Zhen-Hui Wu
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-28       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.